Ori Biotech To Use $30M Series A On Cell, Gene Therapy Manufacturing Platform
The London and Woodcliff Lake, New Jersey-based company is developing a platform that closes, automates and standardizes manufacturing for cell and gene therapy developers so they can move their treatments from the pre-clinical process through to scale commercially.
The company has been working with external partners over the past four months doing testing. One partner is already getting good results from testing the platform on its treatment for solid tumors, Ori Biotech’s CEO Jason Foster said in an interview.
Last chance to join our Zoom conversation about the U.K health tech industry and the opportunities available to New Mexico companies for collaboration, market entry including STEP grant funding!
Click here to find more information.
On Wednesday 21st October Elective & Emergency Care Improvement Support Team are supporting #FabChange20 by helping to 'Fab Up' communications this year by a dedicated special radio sign in #GB1FAB on #HamRadio